• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Long-term oral anticoagulation for atrial fibrillation in low and middle income countries
Discussions regarding oral anticoagulation (OAC) use in low and middle income countries (LMICs) have historicallybeendominated by severallong-held beliefs. The first is that the quality of vitamin K antagonist (VKA) based anticoagulation is poor in these countries. The veracity of this assumption is supported by a large number of studies documenting both lower prescription of OACs, and a lower proportion of international normalised ratio (INR) values in the therapeutic range.1The second is that a large proportion of patients receiving OAC in LMICs have atrial fibrillation (AF) related to valvular heart disease, and rheumat...
Source: Indian Heart J - April 18, 2021 Category: Cardiology Authors: Venkatakrishnan Ramakumar Alexander P Benz Ganesan Karthikeyan Source Type: research

Inhibition of Platelet Aggregation After Coronary Stenting in Patients Receiving Oral Anticoagulation
CONCLUSION: After coronary stent implantation, dual therapy with a NOAC and a P2Y12 inhibitor is recommended, subsequent to triple therapy given only during the peri-interventional period.PMID:33637173 | DOI:10.3238/arztebl.m2021.0150
Source: Deutsches Arzteblatt International - February 27, 2021 Category: General Medicine Authors: Conrad Genz Ruediger C Braun-Dullaeus Source Type: research

Peak plasma rivaroxaban levels in patients weighing 120  kg or greater
Direct oral anticoagulants (DOACs) have become the drug of choice, increasingly replacing traditional vitamin K antagonists (VKA) for stroke prevention in atrial fibrillation (AF) and in the treatment of venous thromboembolism (VTE) due to their advantages of fixed dosing and no requirement for drug monitoring. Furthermore, their use is expanding into the ischemic heart disease population [1]. However, there is ongoing concern regarding their use in those weighing ≥120 kg or who have a body mass index (BMI) ≥ 40 due to limited representation of this patient group in the phase 3 DOAC trials [2,3].
Source: Thrombosis Research - February 17, 2021 Category: Hematology Authors: Jameel Abdulrehman, Rita Selby, Raed A. Joundi, Erik Yeo Tags: Letter to the Editors-in-Chief Source Type: research

Peak plasma rivaroxaban levels in patients weighing 120  kg or greater
Direct oral anticoagulants (DOACs) have become the drug of choice, increasingly replacing traditional vitamin K antagonists (VKA) for stroke prevention in atrial fibrillation (AF) and in the treatment of venous thromboembolism (VTE) due to their advantages of fixed dosing and no requirement for drug monitoring. Furthermore, their use is expanding into the ischemic heart disease population [1]. However, there is ongoing concern regarding their use in those weighing ≥120 kg or who have a body mass index (BMI) ≥ 40 due to limited representation of this patient group in the phase 3 DOAC trials [2,3].
Source: Thrombosis Research - February 17, 2021 Category: Hematology Authors: Jameel Abdulrehman, Rita Selby, Raed A. Joundi, Erik Yeo Tags: Letter to the Editors-in-Chief Source Type: research

Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients with Atrial Fibrillation and Valvular Heart Disease.
CONCLUSIONS: NOACs had a comparable risk of ischemic stroke and bleeding in patients with AF and VHD, and reduced the risk of venous thromboembolism, intracranial hemorrhage, and mortality, compared to warfarin. Therefore, NOAC is an effective and safe alternative to warfarin in these patients. PMID: 33538623 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - February 6, 2021 Category: Research Tags: Curr Med Res Opin Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11